Holen Sie sich die Stockscreener-App
6.38
13.73%
0.77
Handel nachbörslich:
6.50
0.12
+1.88%
Schlusskurs vom Vortag:
$5.61
Offen:
$5.52
24-Stunden-Volumen:
36,025
Relative Volume:
0.12
Marktkapitalisierung:
$19.91M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-68.80M
KGV:
-5.453
EPS:
-1.17
Netto-Cashflow:
$-59.06M
1W Leistung:
+12.80%
1M Leistung:
+1,491%
6M Leistung:
+1,119%
1J Leistung:
+714.92%
1-Tages-Spanne:
$5.52
$6.73
1-Wochen-Bereich:
$5.4092
$6.73
52-Wochen-Spanne:
$0.257
$7.6996
Passage Bio Inc Stock (PASG) Company Profile
Firmenname
Passage Bio Inc
Sektor
Branche
Telefon
(267) 866-0312
Adresse
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Vergleichen Sie PASG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
6.38 | 17.50M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-29 | Fortgesetzt | Wedbush | Outperform |
| 2024-09-03 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-03-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-01-19 | Herabstufung | Goldman | Buy → Neutral |
| 2021-07-01 | Eingeleitet | Raymond James | Outperform |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-03-04 | Hochstufung | Goldman | Neutral → Buy |
| 2021-02-04 | Eingeleitet | Guggenheim | Buy |
| 2021-01-25 | Eingeleitet | Wedbush | Outperform |
| 2021-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-11 | Eingeleitet | Citigroup | Neutral |
| 2020-08-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-25 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-25 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-03-24 | Eingeleitet | Cowen | Outperform |
| 2020-03-24 | Eingeleitet | Goldman | Buy |
| 2020-03-24 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Passage Bio Inc Aktie (PASG) Neueste Nachrichten
Real time alert setup for Passage Bio Inc. performanceQuarterly Market Summary & Risk Managed Investment Strategies - Newser
What to do if you’re stuck in Passage Bio Inc.IPO Watch & Accurate Entry and Exit Point Alerts - Newser
Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights - GlobeNewswire
Recovery Setup Building in Passage Bio Inc. Experts Say2025 Technical Overview & Fast Moving Trade Plans - 선데이타임즈
Understanding Passage Bio Inc.’s price movement2025 Buyback Activity & Verified Short-Term Trading Plans - Newser
Can swing trading help recover from Passage Bio Inc. losses [Analyst Upgrade]Real-Time Price Movement Reports - Newser
Passage Bio Reports Q2 2025 Progress and Financials - TipRanks
Why Passage Bio Inc. stock attracts strong analyst attentionSupport Level Bounce Alerts - newsyoung.net
Passage Bio, Inc. shares rise 4.99% after-hours after reporting positive interim data for PBFT02. - AInvest
Passage Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Strategies to average down on Passage Bio Inc.Machine Learning Stock Movement Detector - Newser
Forecasting Passage Bio Inc. price range with options dataReal-Time Entry Forecast with Accuracy Metrics - Newser
Passage Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
What makes Passage Bio Inc. stock price move sharplyStock Picks with 300% Gain - kangso.co.kr
Passage BIO, Inc. SEC 10-Q Report - TradingView
Passage Bio Reports Robust FTD-GRN Data, Submits Amended Study Protocol - AInvest
Passage Bio's FTD Drug Shows Breakthrough Results: CSF Biomarker Hits Healthy Range - Stock Titan
Passage Bio Inc. stock outlook for YEARMinimal Risk Growth Investment Opportunity Analysis - Newser
Published on: 2025-08-12 04:09:31 - Newser
Can swing trading help recover from Passage Bio Inc. lossesFree Opportunity Map for Daily Stock Trading - Newser
Passage Bio PASG 2025Q2 Earnings Preview Downside Risk Amid Revenue Challenges - AInvest
Risk vs reward if holding onto Passage Bio Inc.Predictive Short-Term Market Reversal Alerts - Newser
What analysts say about Passage Bio Inc. stock outlookSummary of Trade Cycles in 5-Year Range - Newser
Technical signs of recovery in Passage Bio Inc.Weekly Hot Stocks Based on Volume Flow - Newser
Published on: 2025-08-11 01:24:13 - Newser
Passage Bio Inc. stock volume spike explainedAI-Based Reversal Point Prediction Signal - Newser
Sentiment analysis tools applied to Passage Bio Inc.ROI Focused Watchlist with Trade Confidence - Newser
Will Passage Bio Inc. Stock Benefit from AI and Green Energy TrendsAsset Growth Pattern and Return Summary - Newser
Tick level data insight on Passage Bio Inc. volatilityLoss Limitation Strategy Based on Analysis - Newser
What moving averages say about Passage Bio Inc.Free Early Breakout Entry Point Notifications - Newser
Tools to assess Passage Bio Inc.’s risk profileWeekly Breakout Forecast with Entry Zones - Newser
Is Passage Bio Inc. a candidate for recovery playWeekly Hot Stocks Based on Volume Flow - Newser
Passage Bio (PASG) Projected to Post Earnings on Thursday - Defense World
Is Passage Bio Inc. Stock a Good Fit for Conservative InvestorsMomentum Based Equity Trading Plans Reviewed - metal.it
Passage Bio Inc expected to post a loss of $4.05 a shareEarnings Preview - TradingView
Is Passage Bio Inc. a good long term investmentCapitalize on fast-growing stocks today - Jammu Links News
Passage Bio Inc. Stock Analysis and ForecastBuild a diversified portfolio for stability - Jammu Links News
What are Passage Bio Inc. company’s key revenue driversUnlock rapid growth potential in your portfolio - Jammu Links News
Finanzdaten der Passage Bio Inc-Aktie (PASG)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):